Interactive

NMA lab

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Pick an analysis, remove treatments or trials, and refit it in your browser. The lab uses line by line TypeScript ports of the two R packages behind the published results: netmeta for the frequentist graph theoretical model and multinma for the Bayesian random effects model, with the same priors and settings. Nothing you do here is sent anywhere.

417 analyses

HbA1c change
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 59 trials, 33 treatments
HbA1c change
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 58 trials, 44 treatments
HbA1c change
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); each dose separately; 21 trials, 32 treatments
HbA1c change
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); doses of a drug pooled; 20 trials, 19 treatments
HbA1c change
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 19 trials, 20 treatments
HbA1c change
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 19 trials, 13 treatments
HbA1c change
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 14 trials, 17 treatments
HbA1c change
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 14 trials, 26 treatments
HbA1c change
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); each dose separately; 13 trials, 20 treatments
HbA1c change
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); doses of a drug pooled; 12 trials, 13 treatments
HbA1c change
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); doses of a drug pooled; 9 trials, 10 treatments
HbA1c change
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); each dose separately; 9 trials, 13 treatments
HbA1c change
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 8 trials, 9 treatments
HbA1c change
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 8 trials, 12 treatments
HbA1c change
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 8 trials, 8 treatments
HbA1c change
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 8 trials, 6 treatments
HbA1c change
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 8 trials, 6 treatments
HbA1c change
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 7 trials, 9 treatments
HbA1c change
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 5 trials, 5 treatments
HbA1c change
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); each dose separately; 5 trials, 12 treatments
HbA1c change
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); doses of a drug pooled; 5 trials, 7 treatments
HbA1c change
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 5 trials, 9 treatments
HbA1c change
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 4 trials, 4 treatments
HbA1c change
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 4 trials, 6 treatments
HbA1c change
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 4 trials, 3 treatments
HbA1c change
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 4 trials, 3 treatments
HbA1c change
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); doses of a drug pooled; 3 trials, 4 treatments
HbA1c change
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 3 trials, 4 treatments
HbA1c change
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); each dose separately; 3 trials, 8 treatments
HbA1c change
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 3 trials, 4 treatments
HbA1c change
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 3 trials, 2 treatments
HbA1c change
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 3 trials, 4 treatments
HbA1c change
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); each dose separately; 3 trials, 9 treatments
HbA1c change
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); doses of a drug pooled; 3 trials, 4 treatments
HbA1c change
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 3 trials, 2 treatments
HbA1c change
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 3 trials, 4 treatments
HbA1c change
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); doses of a drug pooled; 2 trials, 2 treatments
HbA1c change
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); doses of a drug pooled; 2 trials, 3 treatments
HbA1c change
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); doses of a drug pooled; 2 trials, 4 treatments
HbA1c change
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); each dose separately; 2 trials, 4 treatments
HbA1c change
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); each dose separately; 2 trials, 3 treatments
HbA1c change
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 2 trials, 2 treatments
HbA1c change
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 2 trials, 3 treatments
HbA1c change
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 2 trials, 4 treatments
HbA1c change
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 2 trials, 4 treatments
HbA1c change
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); doses of a drug pooled; 2 trials, 4 treatments
HbA1c change
Type 2 diabetes (adults); weeks 64 to 130 (target week 104); each dose separately; 2 trials, 4 treatments
HbA1c change
Type 2 diabetes (adults); weeks 64 to 130 (target week 104); doses of a drug pooled; 2 trials, 3 treatments
HbA1c change
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 2 trials, 4 treatments
HbA1c change
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 2 trials, 6 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 50 trials, 28 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 49 trials, 38 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); doses of a drug pooled; 19 trials, 19 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 18 trials, 18 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 18 trials, 11 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); each dose separately; 17 trials, 30 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); doses of a drug pooled; 11 trials, 12 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 10 trials, 20 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); each dose separately; 10 trials, 18 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 9 trials, 13 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); doses of a drug pooled; 8 trials, 9 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 8 trials, 6 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 8 trials, 8 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 8 trials, 6 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 7 trials, 7 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 7 trials, 8 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 7 trials, 10 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 4 trials, 8 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); each dose separately; 4 trials, 8 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); each dose separately; 4 trials, 5 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); each dose separately; 4 trials, 11 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); doses of a drug pooled; 4 trials, 6 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 4 trials, 3 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 4 trials, 3 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 4 trials, 5 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); each dose separately; 3 trials, 9 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); each dose separately; 3 trials, 8 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 3 trials, 4 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 3 trials, 4 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 3 trials, 2 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 3 trials, 2 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); doses of a drug pooled; 3 trials, 4 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); doses of a drug pooled; 3 trials, 4 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 3 trials, 4 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 3 trials, 4 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 2 trials, 4 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 2 trials, 4 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); each dose separately; 2 trials, 3 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 2 trials, 2 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 64 to 130 (target week 104); doses of a drug pooled; 2 trials, 3 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); each dose separately; 2 trials, 4 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 64 to 130 (target week 104); each dose separately; 2 trials, 4 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); each dose separately; 2 trials, 2 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 64 to 130 (target week 104); doses of a drug pooled; 2 trials, 3 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); doses of a drug pooled; 2 trials, 3 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); doses of a drug pooled; 2 trials, 3 treatments
Body weight change in kilograms (diabetes)
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 2 trials, 4 treatments
HbA1c below 7 percent
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 17 trials, 17 treatments
HbA1c below 7 percent
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 16 trials, 23 treatments
HbA1c below 7 percent
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 10 trials, 16 treatments
HbA1c below 7 percent
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 10 trials, 10 treatments
HbA1c below 7 percent
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 7 trials, 8 treatments
HbA1c below 7 percent
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 7 trials, 14 treatments
HbA1c below 7 percent
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); each dose separately; 5 trials, 9 treatments
HbA1c below 7 percent
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); doses of a drug pooled; 4 trials, 5 treatments
HbA1c below 7 percent
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 4 trials, 5 treatments
HbA1c below 7 percent
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 4 trials, 7 treatments
HbA1c below 7 percent
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); doses of a drug pooled; 4 trials, 6 treatments
HbA1c below 7 percent
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); doses of a drug pooled; 4 trials, 6 treatments
HbA1c below 7 percent
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); each dose separately; 4 trials, 11 treatments
HbA1c below 7 percent
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); doses of a drug pooled; 4 trials, 6 treatments
HbA1c below 7 percent
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); each dose separately; 4 trials, 8 treatments
HbA1c below 7 percent
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); each dose separately; 3 trials, 8 treatments
HbA1c below 7 percent
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 3 trials, 2 treatments
HbA1c below 7 percent
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 3 trials, 2 treatments
HbA1c below 7 percent
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 2 trials, 4 treatments
HbA1c below 7 percent
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 2 trials, 4 treatments
HbA1c below 7 percent
Type 2 diabetes (adults); weeks 36 to 64 (target week 52); each dose separately; 2 trials, 4 treatments
HbA1c below 7 percent
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); each dose separately; 2 trials, 3 treatments
HbA1c below 7 percent
Type 2 diabetes (adults); weeks 20 to 36 (target week 26); doses of a drug pooled; 2 trials, 3 treatments